Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for hypomagnesemia in ADTKD-HNF1β
NL-OMON51437Phase 3Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dapagliflozin in hypomagnesaemia and autosomal dominant tubulointerstitial kidney disease (ADTKD) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Change in serum magnesium. Started May 2023; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
hypomagnesaemiaautosomal dominant tubulointerstitial kidney disease (ADTKD)
Beyond the preview
Go deeper on NL-OMON51437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51437.